Cyclo Therapeutics Inc. (NASDAQ: CYTH)
$0.6155
+0.0135 ( +4.32% ) 33.1K
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Market Data
Open
$0.6155
Previous close
$0.6020
Volume
33.1K
Market cap
$16.53M
Day range
$0.5690 - $0.6300
52 week range
$0.5690 - $2.1150
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Aug 20, 2024 |
4 | Insider transactions | 1 | Aug 20, 2024 |
4 | Insider transactions | 1 | Aug 20, 2024 |
4 | Insider transactions | 1 | Aug 20, 2024 |
10-q | Quarterly Reports | 63 | Aug 14, 2024 |
8-k | 8K-related | 16 | Jul 17, 2024 |
8-k | 8K-related | 16 | Jun 11, 2024 |
4 | Insider transactions | 1 | Jun 05, 2024 |
4 | Insider transactions | 1 | Jun 05, 2024 |
4 | Insider transactions | 1 | Jun 05, 2024 |